Dr Paul Dargan & Dr David Wood Consultant Clinical Toxicologists Guy’s and St Thomas’ NHS Foundation Trust London, UK Monitoring Drug Emergencies How and.

Slides:



Advertisements
Similar presentations
NDTMS data on club drugs and NPS
Advertisements

REPORT Full report Executive summary Methodology STATISTICAL ANNEX Seizures Drug use Prices Illicit laboratories.
What can Europe learn from the US experience of policy-related drugs monitoring? Terry Zobeck, Ph.D. Office of National Drug Control Policy Executive Office.
Responding to the Patient’s Voice: the importance of Patient Reported Outcomes Dr. Kirstie Haywood Senior Research Fellow RCN Research Institute, School.
Unintentional Drug Poisoning Deaths, Michigan Residents, Su Min Oh, PhD Michigan Department of Community Health Bureau of Substance Abuse and.
Towards a New R&D Strategy A blueprint for R&D in Health and Social Care Noreen Caine Deputy Director of R&D, DH NHS R&D Forum Annual Conference May 2005.
Three datasets are better than one! Alcohol related diagnoses from ambulance to hospital admission, Melbourne, Australia Sharon Matthews Jason Ferris Belinda.
Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction Robert W. Yeh, MD MSc Massachusetts General Hospital Alan S. Go, MD Kaiser.
Delivering independent intelligence for health and wellbeing Background to NDTMS & TOP - a context for data collection Jill Smith Public Health Liaison.
National Service Framework for diabetes Ruth BarnesMina Fernando Director of Public HealthDiabetes Manager.
ROLE OF DRUGS Lesson Essential Question: How does drug dependency lead to violent crimes?
2 emcdda.europa.eu European drug report package A comprehensive analysis on the drugs problem in Europe.
National rapid access to best-quality stroke services Prevent 1 stroke every day Avoid death or dependence in 1 patient every day National Stroke Clinical.
European Early Warning System Charlotte Davies. European Early Warning System Adopted in May 2005, the Council Decision 2005/387/JHA on the information.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Drug Trends in Washington State & King County Caleb J. Banta-Green MPH MSW Alcohol & Drug Abuse Institute University of Washington
Selection of Data Sources for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
NAPHSIS Annual Meeting 2014Slide 1 NAPHSIS ANNUAL MEETING | Seattle | June 8-11, 2014 VITAL RECORDS: A CULTURE OF QUALITY Washington State’s approach to.
LEGAL AND ILLEGAL SUBSTANCES. LEGAL DRUGS Legal drugs are considered permissible for use, and are either prescribed by a physician (prescription medications)
The UK Drugs Situation: Data, information and uses Charlotte Davies, UK Focal Point Project Manager 1.
Factors associated with fatal overdoses in Oslo Linn Gjersing, Thomas Clausen, Jørgen Bramness, Helge Waal, Stian Biong & Edle Ravndal.
Research Techniques Made Simple: Databases for Clinical Research Katrina Abuabara, MD MA David Margolis, MD PhD University of Pennsylvania.
TEMPLATE DESIGN © Prevalence of educational qualifications and access to information technologies in patients with acute.
SLIDE 1 of 34 IS THERE A CAUSAL RELATIONSHIP BETWEEN SUBSTANCE ABUSE AND PSYCHIATRIC ILLNESS? Dr Martin Frisher Department of Medicines Management Keele.
Polydrug use challenges – European experience International Conference: New trends in drug use: facts and solutions, Parliament of the Republic of Vilnius.
Respiratory Benchmarking Packs Yorkshire and the Humber September 2010.
Annual report 2010: the state of the drugs problem in Europe.
Annual report 2009: the state of the drugs problem in Europe International Conference: New trends in drug use: facts and solutions, Parliament of the Republic.
Annual report 2009: the state of the drugs problem in Europe NB Embargo 5 November :00 CET (Brussels time)
The EuroHOPE- project: Comparison of treatment and outcome for AMI and stroke patients in Europe On behalf of the EuroHOPE-team: Terje P. Hagen Department.
Public Health England: opportunities for better coverage? Professor John Newton, Chief Knowledge Officer, Public Health England.
Office for National Statistics & Public Health Dr Azeem Majeed Office for National Statistics & University College London.
Liverpool Community Alcohol Services 0151 – 259 –
HCV in injecting drug users: developing indicators of prevalence and responses VHPB WHO Consultation Meeting Geneva, 13 May 2002 Lucas Wiessing European.
Developments & Issues in the Production of the Summary Hospital-level Mortality Indicator (SHMI) Health and Social Care Information Centre (HSCIC)
Linda Montanari, Buenos Aires, October 2003 CICAD/OAS, Demand Reduction Experts Group Meeting The Information System on Treatment Demand in EU EMCDDA.
Databases Using them to study MS in the UK. Proposed research using: GPRD (General Practice Research Database) MSNTC Northwood Database.
MS Procedural Coding Controlled Drugs MHA May 21, 2009 Irene Mueller, EdD, RHIA.
Gerhard Bühringer, Monika Sassen Institut für Klinische Psychologie und Psychotherapie Institut für Therapieforschung, München EMCDDA work and scientific.
Know your Drug Classification Match the following drugs as to how they effect the central nervous system. To end the program at any time- push the Esc.
Chronic diseases as tracer conditions in international benchmarking of health systems: the example of diabetes 1 European Centre on Health of Societies.
The Balance of Care Group in association with Lincolnshire Partnership Trust, Lincolnshire PCT, United Lincolnshire Hospitals NHS Trust, Lincolnshire County.
Illicit Drugs. Case Study 14 year-old boy was admitted to PICU with acute paralysis: Rt hemiplegia and Lt hemiparesis Urine was positive for MDMA (Ecstasy)
Chapter 5 Drugs.  Drug – natural or synthetic substance used to produce physiological or psychological effects in humans  More than 75% of the evidence.
Hospital inpatient data James Hebblethwaite. Acknowledgements This presentation has been adapted from the original presentation provided by the following.
NPS and Importance of Information Sharing Dr Richard Stevenson A&E Department, Glasgow Royal Infirmary Dr Hazel Torrance Forensic Medicine and Science.
Overview of the cannabis use in Europe Paul Griffiths, Reitox academy, Berlin, 29th March 2007.
A ssociation of Public Health Observatories Hospital Activity data Roy Maxwell SWPHO & Bristol University Dr Richard Wilson Sandwell PCT.
Implementing Clinical Governance COMPASS Consultant Outcome Indicators Programme.
Some epidemiological principles and methods
Outcomes in AKI, the national audit
Lancet. 2017 Aug 5;390(10094): doi: /S (17) Epub 2017 May 25.
Drug Classifications.
Chapter 9 -- Drugs Drug: a substance that is used to produce physiological or psychological effects. Drug abuse – a brief history In the 1960s, the main.
MODULE 2- EPIDEMIOLOGY OF DRUG USE IN THE AMERICAS
Professor Paul I Dargan
The landscape of prescription drug misuse in the UK
History of Drugs and the Legislation made to control them
The European Experience: Prescription Drug Misuse in France, Germany, Italy and Spain 24 October 2017 Presented at Lisbon Addictions 2017 Jody L. Green,
DRUG CLASSIFICATIONS.
Comparison of data from WBE with other sources
Module 1: Putting Drugs of Abuse and Clients in Perspective
Drug use among MSM (overview with focus on chemsex)
The Euro-Drug Emergencies Network (Euro-DEN) ED presentations with acute toxicity related to the misuse of prescription medicines Professor Paul.
Non-fatal poisoning with illicit drugs in Denmark
Toxicology Drugs and Poisons.
Integrated Care System (ICS) Berkshire West
Poison- Murder, Accidental Overdoses, and Drug Offences
Skopje, 21 November 2017, General Population Survey results– launch
Presentation transcript:

Dr Paul Dargan & Dr David Wood Consultant Clinical Toxicologists Guy’s and St Thomas’ NHS Foundation Trust London, UK Monitoring Drug Emergencies How and Why Should We Do It?

Recreational Drugs EMCDDA Annual Report 2008  Recreational Drug use is common  Numerous National, European and International networks collect data on recreational drug use: i Population surveys of drug use  Life-time prevalence of drug use in Europe: –22% cannabis –3.6% cocaine –2.8% ecstasy –Variations in pattern of use across EU

Recreational Drugs  Recreational Drug use is common  Numerous National, European and International networks collect data on recreational drug use: i Population surveys of drug use ii Drug seizures, crime reports / surveys iii Use of treatment agencies for problem drug use iv Drug-related fatalities  Less co-ordinated data on recreational drug toxicity

Acute Recreational Drug Toxicity  There is the potential for significant morbidity and mortality  This is dependent on the class of drug

Stimulants Hallucinogenics Depressants MDMA (ecstasy) Amphetamine Cocaine 1-benzylpiperazine GHB / GBL 1,4-butanediol Heroin Opium LSD Ketamine Glaucine TFMPP Acute Recreational Drug Toxicity

Acute Recreational Drug Toxicity What data is available?  No currently published National Datasets  Not routinely collected by EMCDDA Reitox National Focal Points Hospital coding of admissions (discharges):  Often only capture admitted patients –up to 50-75% managed in Emergency Departments or pre-hospital  Based on ICD-10

Acute Recreational Drug Toxicity ICD-10  ICD-10 codes: –Dependent on cases being coded appropriately –Not specific for all recreational drug presentations e.g. MDMA, amphetamines, ketamine, GHB not captured

T40.0Opium T40.1Heroin T40.2Other opioids (codeine, morphine) T40.3Methadone T40.4Other synthetic narcotics (pethidine) T40.5Cocaine T40.6Other and unspecified narcotics T40.7Cannabis (derivatives) T40.8Lysergide [LSD] T40.9Other & unspecified psychodysleptics [hallucinogens] Mescaline, psilocin, psilocybine ICD-10 recreational drug codes T40: Poisoning by narcotics and psychodysleptics

 Poisons Information Services –Only capture cases that clinicians call about  Ambulance / Pre-Hospital data sets –UK: >90% cases brought to hospital by ambulance –Ambulance datasets not widely available / published –No standard EU / International coding system –Pilot studies in UK: coding not sufficient to provide reliable / robust data on recreational drug toxicity Acute Recreational Drug Toxicity Other Potential Datasets

 Link in to other established, validated national clinical datasets –National Disease Registers –Stroke Registers –Cardiovascular Disease Registers  Would require novel data capture for recreational drug coding  Could potentially allow prospective follow up of a cohort of patients Acute Recreational Drug Toxicity Other Potential Datasets

 Single centre datasets –Collected within a hospital / city / region –Requires local interest, finance and logistics –Provide valuable information, with clinical detail, particularly in a high incidence area –e.g. London UK, Palma Mallorca, Oslo Norway Acute Recreational Drug Toxicity Other Potential Datasets

 Single centre datasets –Collected within a hospital / city / region  Potential to link these single centre datasets –Current EMCDDA funded pilot study led by us –Looking at data collection in London and Mallorca –Using a limited dataset -Demographics and exposure data -Basic clinical parameters and outcome Acute Recreational Drug Toxicity Other Potential Datasets

 Single centre datasets –Collected within a hospital / city / region  Potential to link these single centre datasets –Current EMCDDA funded pilot study led by us –Looking at data collection in London and Mallorca –Will allow comparison of epidemiology between specialist centres –Potential to expand to other centres Acute Recreational Drug Toxicity Other Potential Datasets

London Acute Recreational Drug Toxicity Data  Guy’s and St Thomas’ NHS Foundation Trust –Central London Teaching Hospital –Specialist Clinical Toxicology Service  Purpose designed database: –Detailed data on all poisoned patients –Full-time database scientist –1600 acute poisoning presentations per year –39% relate to recreational drug toxicity Greene SL Postgrad Med J 2008

Recreational Drug Presentations (2008)

Recent Trends and Other Results :  Increase in cocaine-related toxicity  Increase in GHB/GBL presentations  Increase in GBL:GHB ratio  Differences in pre-hospital and Emergency Department datasets  Methamphetamine toxicity is not an issue in London or elsewhere in the UK Wood DM QJM 2008, Wood DM Subst Use Misuse 2009

Users Self-Report vs Toxicological Screening  This and other similar datasets rely on users self-report  Studies suggest users self-report variable in determining the primary drug(s) responsible for toxicity West E Emerg Med Australas 2008, Brojnaas MA Clin Tox 2006  Users self-report not useful in the context of: –Novel / emerging drugs –Mis-appropriated drugs

Novel Recreational Drugs  In the last 3 years we’ve detected 9 novel recreational drugs e.g. piperazines, glaucine, DOC, D2PM, cathinones  On an ad hoc basis using clinical suspicion in patients with an atypical history / clinical features  Increasing availability/use of novel recreational drugs  Incidence of novel recreational drug toxicity is unknown  This could only be determined using comprehensive toxicological screening in a busy specialist centre Wood DM Lancet 2007, Staack R Lancet 2007, Dargan PI EJCP 2008, Ovaska H EJEM 2008, Lidder S J Med Toxicol 2008, Wood DM J Med Toxicol 2008

Conclusions  Acute recreational drug toxicity: significant morbidity  ICD-10 not suitable for data collection: –Poor availability of national / EU data  Potential datasets –Links to established disease registers –Pooling of single centre, specialist datasets  Screening of recreational drug presentations in a large centre to determine –the drugs responsible for toxicity –incidence of novel recreational drug toxicity